OKYO
NASDAQOKYO Pharma Limited
OKYO Pharma Limited (OKYO) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 2 wire items for OKYO, including 1 press release or news item and 1 SEC filing. The most recent was published Nov 5, 2026.
Financial highlights
Full financials- Revenue, FY2026
- $32.1K
- Revenue growth
- +486.5%
- Net income, FY2026
- -$8.95M
- Net margin
- -27882.3%
- Free cash flow, FY2026
- -$5.94M
- Cash
- $14.59M
For fiscal 2026 (ended Mar 31, 2026), from SEC filings. Not investment advice.
News · 26 weeks64-50%
2026-05-102026-11-01
Mix1090d
- Other5(50%)
- SEC Filings5(50%)
Latest news
25 items- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- PROKYO Pharma to Present at the Stifel 2026 Healthcare ConferenceLONDON and NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will participate at the Stifel 2026 Healthcare Conference November 10–12, 2026. Robert J. Dempsey, Chief Executive Officer, is scheduled to present at 9:20 a.m. ET on Thursday, November 12, 2026, at the Stifel 2026 Healthcare Conference to be held at the Lotte New York Palace Hotel, New York, NY. In addition to presenting, OKYO Leadership will be available for one-on-one investor meetings throughout the conferen
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- PROKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal PainNEPTUNE is evaluating urcosimod as a potential first-in-class treatment for neuropathic corneal painFirst patients enrolled by Dr. Melissa Toyos at Toyos Clinic in Nashville, TN LONDON and NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced first patients enrolled in Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain (NCP). "Neuropathic corneal pain is one of the most debilitating conditions I see in my practice, and right now we have no FDA approved therapy to offer
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- PROKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific ConferencesOKYO demonstrates continued commitment to optometry and ophthalmology LONDON and NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will present and participate at upcoming ophthalmic conferences. Upcoming Scientific Conferences: Eyecelerator: October 8, 2026New Orleans, Louisiana Presentation Title: Addressing Unmet Needs in Corneal and Anterior Segment DiseasesPresentation Date/Time: Thursday, October 8, 2026, 1:29 PM CTBreakout: Anterior Segment, Room 243-245Present
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- PROKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026LONDON and NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will present at Ophthalmology Futures Forum and in the 5th Annual ESCRS iNovation Day. Ophthalmology Futures European Forum on Thursday, September 10 in London is where clinical innovators, investors, and industry leaders convene to examine what's next in ophthalmology and where the next wave of value will be created. ESCRS iNovation Day, taking place Friday, September 11, 2026 at ExCeL London, United Kingdom,
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- PROKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare ConferenceLONDON and NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced participation at the Cantor Global Healthcare Conference being held September 9-11, 2026. Details of the event are as follows: Presenters: Flavio Mantelli, MD, PhD, Chief Medical Officer, Gary Jacob, PhD, Chief Development Officer Date/Time: Thursday, September 10 at 8:35 AM ET Moderator: Eric Fitzgerald, Cantor Fitzgerald The Company will be available for one-on-one meetings during the conference. The Company's
- SECAmendment: SEC Form 20-F/A filed by OKYO Pharma Limited20-F/A - OKYO Pharma Ltd (0001849296) (Filer)
- INSIDERAmendment: CHIEF DEVELOPMENT OFFICER Jacob Gary S bought $4,900 worth of shares (3,500 units at $1.40), increasing direct ownership by 3% to 112,420 units (SEC Form 4)4/A - OKYO Pharma Ltd (0001849296) (Issuer)
- INSIDERAmendment: CHIEF EXECUTIVE OFFICER Dempsey Robert John bought $23,085 worth of shares (15,000 units at $1.54) (SEC Form 4)4/A - OKYO Pharma Ltd (0001849296) (Issuer)
- INSIDERAmendment: Director Brancaccio John P bought $7,385 worth of shares (5,000 units at $1.48), increasing direct ownership by 17% to 35,201 units (SEC Form 4)4/A - OKYO Pharma Ltd (0001849296) (Issuer)
- INSIDERAmendment: Chief Scientific Officer Patil Rajkumar V. bought $5,011 worth of shares (3,363 units at $1.49), increasing direct ownership by 20% to 20,030 units (SEC Form 4)4/A - OKYO Pharma Ltd (0001849296) (Issuer)
- INSIDERAmendment: Director Cerrone Gabriele M bought $35,000 worth of shares (25,000 units at $1.40) (SEC Form 4)4/A - OKYO Pharma Ltd (0001849296) (Issuer)
- INSIDERAmendment: Director Cerrone Gabriele M bought $32,625 worth of shares (22,500 units at $1.45) (SEC Form 4)4/A - OKYO Pharma Ltd (0001849296) (Issuer)
- INSIDERAmendment: CHIEF MEDICAL OFFICER Mantelli Flavio bought $28,000 worth of shares (20,000 units at $1.40) (SEC Form 4)4/A - OKYO Pharma Ltd (0001849296) (Issuer)
- INSIDERChief Scientific Officer Patil Rajkumar V. was granted 3,363 shares, increasing direct ownership by 20% to 20,030 units (SEC Form 4)4 - OKYO Pharma Ltd (0001849296) (Issuer)
- INSIDERNew insider Patil Rajkumar V. claimed ownership of 16,667 shares (SEC Form 3)3 - OKYO Pharma Ltd (0001849296) (Issuer)
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- PROKYO Pharma Announces Purchase of Shares by Chief Scientific OfficerLONDON and NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Raj Patil, PhD, Chief Scientific Officer of OKYO Pharma has increased his holdings with the purchase of 3,363 of the Company’s ordinary shares on NASDAQ at $1.49 per share, bringing his total holding to 20,030 ordinary shares. About OKYO PharmaOKYO Pharma Limited (NASDAQ:OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and ant
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- PROKYO Pharma to Participate in the BTIG Biotechnology Conference 2026LONDON and NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced its participation in the BTIG Biotechnology Conference 2026 taking place virtually on July 28-29, 2026. Company Participation: Robert J. Dempsey, Chief Executive Officer, Keeren Shah, Chief Financial Officer, Flavio Mantelli MD, PhD, Chief Medical Officer Date/Time: July 28-29, 2026 Location: Virtual 1:1 Meetings: schedule a one-on-one meeting with management by contacting your BTIG representative About OKYO PharmaO
- INSIDERCHIEF EXECUTIVE OFFICER Dempsey Robert John was granted 15,000 shares (SEC Form 4)4 - OKYO Pharma Ltd (0001849296) (Issuer)
OKYO FAQ
11 questionsWhat does OKYO Pharma Limited do?
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. It is developing OK-101 for the treatment of dry eye disease; and OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. The company is also developing chemerin and chemerin analogues to treat the cytokine release syndrome associated with COVID-19 infections and other conditions, such as acute respiratory distress syndrome. OKYO...What is the latest news on OKYO?
In the last 30 days Quantisnow tracked 2 wire items for OKYO: 1 press release or news item and 1 SEC filing. The most recent was published on November 5, 2026.What is OKYO revenue?
OKYO Pharma Limited (OKYO) reported $32.1K of revenue for fiscal 2026 (ended Mar 31, 2026). That is up 486.5% from the year before.Is OKYO profitable?
No. OKYO Pharma Limited reported a net loss of $8.95M for fiscal 2026 (ended Mar 31, 2026).How much cash and debt does OKYO have?
OKYO Pharma Limited reported $14.59M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does OKYO stock trade?
OKYO Pharma Limited (OKYO) is listed on NASDAQ.What sector and industry is OKYO in?
OKYO Pharma Limited operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did OKYO Pharma Limited go public?
OKYO Pharma Limited (OKYO) completed its IPO in 2022.What are analysts saying about OKYO?
OKYO Pharma Limited has had 2 recent analyst actions on file. The most recent action was from Piper Sandler: Overweight with a $7.00 price target on 2026-02-20. Recent price targets range from $5.00 to $7.00.What companies are similar to OKYO?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare OKYO side-by-side with any of them on Quantisnow.How can I track OKYO on Quantisnow?
Quantisnow aggregates OKYO Pharma Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OKYO to receive live email and push alerts on every new disclosure.